author={Susan J. Keam and Antona J. Wagstaff},
  journal={Treatments in Endocrinology},
SummaryAbstractEthinylestradiol 30μg/drospirenone 3mg (Yasmin®1, petibelle®) [EE/DRSP] is a combined contraceptive pill (CC) for the prevention of pregnancy in women of reproductive age. Drospirenone is a novel progestogen with antimineralocorticoid, progestogenic and antiandrogenic activity.The theoretical (0–0.07) and corrected (0.41–0.71) Pearl indices and pregnancy ratios (0.3–0.84) in young, healthy women aged 18–35 years (or 18–30 years if smokers) given 13–26 cycles of EE/DRSP in large… 

Drospirenone/Ethinylestradiol 3mg/20µg (24/4 Day Regimen)

Clinical trials indicate that drospirenone/ethinylestradiol 3mg/20µg (24/4) is a good long-term contraceptive option, and additionally offers relief of symptoms that characterise PMDD and has a favourable effect on moderate acne vulgaris.

Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women

  • H. BlodeK. KowalKatrin RothS. Reif
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2012
Ethnic origin had no clinically relevant influence on the pharmacokinetics of DRSP and EE in Caucasian and Japanese women.

Sexual behavior and oral contraception: a pilot study.

The treatment with Yasmin® (Bayer-Schering Italia) is associated with increased pain during intercourse, with decreased libido and spontaneous arousability, and with diminished frequency of sexual intercourse and orgasm.

Ethinyl Estradiol/Drospirenone for the Treatment of the Emotional and Physical Symptoms of Premenstrual Dysphoric Disorder

A combined oral contraceptive pill containing 20 μg of ethinyl estradiol and 3 mg of the progestin drospirenone in a novel dose regimen has demonstrated efficacy for the symptoms of premenstrual dysphoric disorder, a severe form of prewomen's syndrome, with an emphasis on the affective symptoms.

Oral contraceptives : Does formulation matter ? OCs come in a variety of formulations

Whether there are significant differences in effectiveness, cycle control (bleeding), side effects, or satisfaction that may help physicians and patients select the appropriate formulation of oral contraceptive formulations is considered.

Predictable benefits of folate-containing combined oral contraceptives after abortion in women: review

Combined oral contraceptives with 30 mcg ethinyl estradiol in combination with drospirenone can effectively suppress hypothalamic-pituitary-ovarian axis excitability after abortion and folate-containing OCs can be used to prevent neural tube defects in the case of pregnancy after withdrawal of OCs.

Scientific Evidences Supporting the Activation of the Renin-Angiotensin-Aldosterone System during Estral Cycle and Pregnancy in Mares

  • K. SatuéA. Muñoz
  • Biology, Medicine
    Selected Chapters from the Renin-Angiotensin System
  • 2020
In mares, the research team has been investigating the changes of RAAS in mares during the estral cycle and during pregnancy, and these results are presented in the current chapter, comparing with the data previously reported for women and laboratory animals.



Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity

Drospirenone exerts potent progestogenic and antigonadotropic activity which was studied in various animal species and efficiently promotes the maintenance of pregnancy in ovariectomized rats, inhibits ovulation in rats and mice and stimulates endometrial transformation in the rabbit.

Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone

  • J. HuberJ. Foidart R. Heithecker
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2000
The combination of 30 g ethinylestradiol/3 mg drospirenone provides effective oral contraception, excellent cycle control, good tolerability and a level of weight loss that may have a significant beneficial effect on compliance in women with a tendency to weight gain due to water retention.

Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol

  • P. RosenbaumW. Schmidt R. Heithecker
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2000
The combination of 3 mg drospirenone/30 μg ethinylestradiol (Yasmin ®, Schering AG) reliably inhibits ovulation, with a low frequency of follicular maturation, and provides a reasonable safety margin.

A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers

In conclusion, drospirenone was absorbed at a similar rate as other synthetic progestogens contained in various oral contraceptives, as indicated by similar tmax values.

Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.

The results of this study show a consistent trend in the reduction of symptoms that suggested a beneficial effect of DRSP/EE for the treatment of PMDD, despite limitations of the study design.

Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women.

It is concluded that DHSP may be a suitable partner of ethinyl estradiol as a constituent of an oral contraceptive, since its progestogenic and antialdosterone profile is similar to that of progesterone.

Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers

Overall, the results indicate that 30 μg ethinylestradiol/3 mg drospirenone has a distinct antimineralocorticoid effect.